S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
NASDAQ:CLBS

Caladrius Biosciences (CLBS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.43
$8.38
52-Week Range
N/A
Volume
466,373 shs
Average Volume
522,308 shs
Market Capitalization
$26.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLBS stock logo

About Caladrius Biosciences Stock (NASDAQ:CLBS)

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.


CLBS Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CLBS Caladrius Biosciences, Inc.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
See More Headlines
Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBS
Employees
27
Year Founded
2006

Profitability

Net Income
$-27,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.54 per share

Miscellaneous

Free Float
59,250,000
Market Cap
$26.05 million
Optionable
Optionable
Beta
0.91

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. David J. Mazzo B.A. (Hons) (Age 65)
    B.Sc. (Hons.), M.Sc., Ph.D., Pres, CEO & Director
    Comp: $957.69k
  • Dr. Kristen K. Buck M.D. (Age 48)
    Exec. VP of R&D and Chief Medical Officer
    Comp: $825k
  • Mr. James Nisco
    VP of Fin. & Treasury
  • Mr. Gregory S. Berkin
    Chief Information Officer
  • Mr. John D. Menditto
    VP of Investor Relations & Corp. Communications
  • Eric Powers
    Director of Communications and Marketing
  • Ms. Gail Holler (Age 63)
    VP of HR
  • Dr. Ian Zhang Ph.D. (Age 57)
    MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc
  • Dr. William K. Sietsema Ph.D. (Age 66)
    VP of Global Regulatory Affairs














CLBS Stock Analysis - Frequently Asked Questions

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.95) by $0.15. During the same period last year, the company posted ($4.35) EPS.

When did Caladrius Biosciences' stock split?

Shares of Caladrius Biosciences reverse split on the morning of Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?

1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend.

What other stocks do shareholders of Caladrius Biosciences own?
This page (NASDAQ:CLBS) was last updated on 2/29/2024 by MarketBeat.com Staff